Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer

Xiao-Li Song, Heoung Keun Kang, Gwang Woo Jeong, Kyu Youn Ahn, Yong Yeon Jeong, Yang Joon Kang, Hye Jung Cho, Chung Man Moon

AIM: To assess intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) for monitoring early efficacy of chemotherapy in a human gastric cancer mouse model.

METHODS: IVIM-DWI was performed with 12 $b$-values (0-800 s/mm$^2$) in 25 human gastric cancer-bearing nude mice at baseline (day 0), and then they were randomly divided into control and 1-, 3-, 5- and 7-day treatment groups ($n = 5$ per group). The control group underwent longitudinal MRI scans at days 1, 3, 5 and 7, and the treatment groups underwent subsequent MRI scans after a specified 5-fluorouracil/calcium folinate treatment. Together with tumor volumes (TV), the apparent diffusion coefficient (ADC) and IVIM parameters [true water molecular diffusion coefficient (D), perfusion fraction (f) and pseudo-related diffusion coefficient (D')] were measured. The differences in the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Conflict-of-interest statement: The authors declared that they have no conflicts of interest to this work.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Heoung Keun Kang, MD, Professor of Medicine, Department of Radiology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do 519-763, South Korea. hkkang@jnu.ac.kr Telephone: +82-61-3797101 Fax: +82-61-3797133

Received: February 24, 2016 Peer-review started: February 25, 2016 First decision: March 31, 2016 Revised: April 12, 2016 Accepted: April 20, 2016 Article in press: April 20, 2016 Published online: June 28, 2016
INTRODUCTION

Gastric cancer (GC) remains the fourth most common malignancy and the second-leading cause of cancer deaths in the world[1]. Despite many advances in cancer diagnosis and treatment, approximately two-thirds of patients are diagnosed with advanced gastric cancer (AGC) in many countries, excluding some trial results in Japanese and South Korean patients[2,3]. For many years, 5-fluorouracil (5-FU)-based chemotherapy has been considered a standard chemotherapy regimen for AGC[4]. Unfortunately, not all patients benefit from this regimen. If an ineffective therapy can be identified at an early stage of treatment, there will be an opportunity to change the therapy approach and clinical management in the individual patient quickly. The response evaluation criteria in solid tumors (RECIST) is widely adopted standard for evaluating therapy response based on the change in tumor size in clinical practice. However, this often takes several weeks to months to develop, and its evaluation period is too long to adjust patient management[5]. Therefore, increasing demands are being placed on imaging modalities to identify early and reliable surrogate markers for the evaluation of therapeutic effect in patients with GC[6].

Core tip: Intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) is useful for monitoring changes of molecular diffusion and microcirculation in gastric cancer at the early stage of chemotherapy. The apparent diffusion coefficient (ADC) and IVIM parameters of true water molecular diffusion coefficient (D) could be reliable marker to detect the necrosis and cellular apoptosis, while perfusion-related IVIM parameters of perfusion fraction (f) and pseudo-related diffusion coefficient (D') are capable of noninvasive assessment of angiogenesis activity in gastric cancer undergoing chemotherapy.

Core tip: Intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) is useful for monitoring changes of molecular diffusion and microcirculation in gastric cancer at the early stage of chemotherapy. The apparent diffusion coefficient (ADC) and IVIM parameters of true water molecular diffusion coefficient (D) could be reliable marker to detect the necrosis and cellular apoptosis, while perfusion-related IVIM parameters of perfusion fraction (f) and pseudo-related diffusion coefficient (D') are capable of noninvasive assessment of angiogenesis activity in gastric cancer undergoing chemotherapy.

Song XL et al. IVIM-DWI in gastric cancer chemotherapy
(DWI) is capable of providing an apparent diffusion coefficient (ADC), which is a measure magnitude of diffusion (of water molecules) within tissue, and has become a favorite choice for oncologic studies[7]. It is well known that a lower ADC is a characteristic of most tumors compared with native tissues because of their high cellularity. An increase in tissue diffusivity, which is induced by an enlarged extracellular space, cell swelling or a loss of membrane integrity under an effective therapy, makes it possible to use ADC to identify the treatment response[8-11]. However, the ADC value derived from DWI based a mono-exponential model does not sufficiently demonstrate the characteristics of tissue behavior. The b-value, which represents the strength and timing of the gradients, determines DWI sensitivity to water motion. When a lower b-value is applied (≤100 s/mm²), microcirculation related protons have relative large diffusion distances, and are capable of changing diffusion signal intensities. In 1986, Le Bihan et al[12] first described the concept of intravoxel incoherent motion (IVIM), which can be used to estimate molecular diffusion and microcirculation in the capillaries separately through bi-exponential fitting of the DWI data using multiple b-values. In recent years, there has been increasing interests in IVIM-DWI, which allows acquisition of quantitative parameters that reflect tissue diffusivity and microcirculation perfusion simultaneously. The true water molecular diffusion coefficient (D), perfusion fractional (f) volume reflective of capillary blood volume and pseudo-related diffusion coefficient associated with capillary network blood flow (D*) can be measured using IVIM-DWI. The blood microcirculation within capillaries can be considered as a type of “pseudo-diffusion” because it has no specific orientation[13].

It has been determined that IVIM-DWI can provide a new opportunity to gain an insight into the perfusion of a tumor without contrast agent administration for preclinical and clinical applications[12,14,15]. Koh et al[16] reported that the calculated f values were lower in colorectal liver metastases, which are characterized by their hypovascular nature, than in the normal liver. In addition, DWI with 10 s/mm² enables the measurement of diffusion and microcirculation contributions in renal allografts as early as 5-d after transplantation[17]. Moreover, IVIM-DWI has been used to evaluate the treatment responses to radiofrequency ablation[18] or a vascular disrupting agent of CKD-516[19] in rabbit model with VX2 liver tumors, and to neoadjuvant chemotherapy in human locoregionally advanced nasopharyngeal carcinoma. Although DWI is increasingly being applied in the body, few studies have focused on gastric lesions due to the limitations of modality of the gastric[20]. Recently, Cheng et al[21] applied IVIM with b-values of up to 1500 s/mm² to evaluate chemotherapeutic efficacy in a gastric cancer xenograft model. In that study, f increased after chemotherapy treatment, which refutes current theories regarding angiogenesis activity within tumors after treatment[22]. A previous IVIM study in prostate cancer also found that f in tumors significantly increased compared to that in normal prostate tissue when a b-value of less than 750 s/mm² was used, while f decrease or became indistinguishable from the normal prostate tissue when high b-values were employed[23]. This phenomenon could be explained by the following theory: The departure of molecular diffusion at very high b-values may have an influence on perfusion-related parameters because both water diffusion and microcirculation contribute to the signal attenuation observed at lower b-values (<100 s/mm²)[13,15]. It should be noted that higher b values may affect the accuracy of the IVIM-derived parameters, which depend heavily on the b-value selection.

Here, we investigate IVIM-DWI with b-values below 800 s/mm² as a potential imaging marker for assessing the early chemotherapy response in term of tissue diffusion and microvascular perfusion, by comparing the tissue cellularity and microvascular density (MVD) properties revealed by histopathological analysis during the full course of treatment using a mouse human gastric cancer xenograft model.

**MATERIALS AND METHODS**

**Animal model**
This study included 25 male adult (6 weeks old) nude mice (BALB/c-nu/nu, Orient Bio, Gwangju, South Korea), each weighing 20-25 g. All mice, fed with a standard diet with water ad libitum, were maintained in appropriate laboratory conditions (a photoperiod of 12 h light and darkness, 50% humidity, 23 ℃). After a two-week adaption period, 1 × 10⁶ human gastric adenocarcinoma AGS cells (ATCC®, CRL-1739™) suspended in 100 μL cold PBS were subcutaneously injected into the lower right hind limbs of the nude mice with a 31 gauge syringe. To evaluate the therapeutic response, the tumor growth curves in each group were estimated based on the morphologic T2-weighted images by using the following formula: TV = π/6 × L × W × H (L, length, W, width, H, height of the tumor).

**Study design**
Following a baseline (day 0) MRI examination, human gastric cancer-bearing mice were randomly divided into control and 1-d, 3-d, 5-d, and 7-d treatment groups (n = 5 per group). 5-fluorouracil (5-FU) (15 mg/kg)/calcium folinate (5 mg/kg) was used for chemotherapy in the treatment groups, while same volume of saline was administered in the control group. 5-FU/calcium folinate was intraperitoneally injected on a bi-daily basis. Mice in the control group underwent longitudinal MRI at days 1, 3, 5 and 7. Each treatment group underwent a second scan with same MRI protocol at days 1, 3, 5, or 7 after treatment. After the MRI examination, mice were euthanized by an
overdose of isoflurane, and the tumor was stripped for further analysis. The short-term 7-d 5-FU treatment was performed, because this study was aimed to investigate the potential of IVIM-DWI for monitoring the early tumor diffusion and perfusion response to treatment.

**MRI protocol**

All MRI scans were performed using 3T MRI (GE Healthcare, Waukesha, WI, United States) with a wrist coil. Mice were placed on a heated pad and anesthetized with 2% isoflurane in oxygen (at a rate of 1.0 L/min) to void movement during imaging. After acquisition of the routine images for localization, a transverse T2-weighted image was obtained using fast spin echo (FSE) sequence [repetition time/echo time (TR/TE), 2000/99.6 ms; section thickness, 3 mm; matrix, 512 × 358; number of excitations (NEX), 4]. Subsequently, IVIM-DWI with 12 b-values (0, 10, 15, 20, 25, 30, 60, 75, 100, 200, 400 and 800 s/mm²) were acquired using a free-breathing single-shot echo-planar imaging (EPI) sequence with application of three diffusion-gradients directions (TR/TE, 2500/66.5; section thickness, 3 mm; number of sections, 8; field of view, 10 × 10 cm²; matrix, 128 × 128; NEX, 4) with an acquisition time of 7 min and 30 s for each study.

**MR imaging analysis**

The acquired datasets were transferred to a GE workstation (Advance Workstation 4.6) and analyzed using an in-house software. The ADC value was calculated by using a liner fit (least-squares fit) mono-exponential model based on the following equation: $S_0/S_0^* = \exp(-b \times ADC)^{[15]}$, where $S_0$ is the signal intensity at a $b$ value of 0 and $S_0^*$ is the signal intensity at higher $b$ values. IVIM parameters was calculated by a nonlinear fit (Levenberg-Marquardt fit) bi-exponential model, and the equation is shown as follow: $S_0/S_0^* = (1-f) \times \exp(-bD) + f \times \exp(-b(D + D^*))^{[15]}$, where D represents true water molecular diffusion coefficient, f and $D^*$ represent perfusion fraction and pseudo-related diffusion coefficient, respectively. A technician with 8 years of experience in MRI measured the tumor sizes and values of ADC, D, f, and $D^*$. The technician was blinded to the information regarding the treatment and control groups.

Regions of interest (ROIs) were drawn by outlining the tumor border on ADC maps, which showed the largest cross-section of the tumor. The ROIs on ADC map were copied and pasted on the corresponding D, f, and $D^*$ maps. In each mouse, the change in tumor volume (TV) relative to the baseline was quantified to determine the treatment response as follows: $\Delta TV\% = \left(\frac{TV_{\text{given time}} - TV_{\text{baseline}}}{TV_{\text{baseline}}}\right) \times 100$, where $TV_{\text{given time}}$ is the tumor volume on day 1, 3, 5, or 7 and $TV_{\text{baseline}}$ is the tumor volume on day 0. For the ADC and IVIM parameters, the percentage changes in values compared to the baseline were recorded by using the following formula: $\Delta Value\% = \left(\frac{Value_{\text{given time}} - Value_{\text{baseline}}}{Value_{\text{baseline}}}\right) \times 100$, where $Value_{\text{given time}}$ is the value on day 1, 3, 5, or 7 and $Value_{\text{baseline}}$ is the value on day 0.

**Histopathological analysis**

The tumor tissue was paraffin-embedded, and sliced in the transverse plane at 0.6 μm intervals to match the corresponding MR image, was selected. The necrotic fraction (NF) of the tumor was evaluated through hematoxylin-eosin (HE) staining. CD31 (Dako, Carpinteria, CA, United States; mouse anti-human; used at 1:200) staining was carried out on pathological specimens by immunohistochemical methods, to analyze the angiogenesis activity of the tumor. The paraffin-embedded sections were incubated with the primary antibody at 4 °C overnight. Secondary antibody (Stem cell Technologies; rabbit anti-mouse; used at 1:300) was applied at room temperature for 1 h and then sections were rinsed with PBS. Positive reaction was visualized by DAB chromogen (Dako, Carpinteria, CA, United States) according to standard methods. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) (Roche Applied Science, Penzberg, Germany) was performed to evaluate cellular apoptosis of the tumor by following the manufacturer's instructions.

Histopathological analysis was performed by using Image J software (http://rsb.info.nih.gov/ij). Tumor necrosis was scored according to the following formula: $NF = \frac{\text{Area necrosis}}{\text{Area total tumor}}$. Cellular apoptosis of the tumor was defined as the percentage of positive TUNEL-stained cells among 200 nuclei from five randomly selected fields at a high magnification (× 200). The mean MVD of the tumor was defined by the CD31-stained vessels[24], where any distinct area of positive for CD31 staining was defined as a single vessel, from five hot spots with higher vascular density compared to the remaining tissue in a high-power field (× 200; 0.578 mm²).

**Statistical analysis**

SPSS 21.0 (SPSS, Chicago, IL, United States) was used for statistical analysis. The differences in relative changes in the ADC and IVIM parameters, and tumor volumes between the control and treatment groups were determined by the Mann-Whitney test. Spearman’s correlation coefficient was used to determine the correlations between histological features, including NF, MVD and TUNEL and the corresponding ADC and IVIM parameters. Spearman’s coefficient was considered to be satisfactory with a critical value of $r_s = 0.415$ at $P < 0.05$ (two-tailed test). A spearman’s coefficient of 0.90-1.00 indicated almost perfect agreement; 0.70-0.90 indicated high agreement; 0.50-0.70 indicate moderate agreement; 0.30-0.50 indicate low agreement; and 0.00-0.30 indicate negligible agreement[25]. A two-tailed $P$ value
treatment, median, 4.98% ± 3.39%, control, June 28, 2016 ± 103.44 mm Twenty-five tumors with a mean volume of 298.07 results in the therapy groups were significantly lower than in the control group at day 5 (ΔTVtreatment% = 19.63% ± 3.01% and ΔTVcontrol% = 83.60% ± 14.87%, P = 0.008) and day 7 (ΔTVtreatment% = 29.07% ± 10.01% and ΔTVcontrol% = 177.06% ± 63.00%, P = 0.008). The difference in ΔTV% between the treatment and the control groups was not significant at day 1 (ΔTVtreatment% = 4.97% ± 4.59% and ΔTVcontrol% = 8.08% ± 2.47%, P = 0.841) or day 3 (ΔTVtreatment% = 15.36% ± 5.75% and ΔTVcontrol% = 23.28% ± 16.76%, P = 0.310) after a short treatment duration.

**IVIM-DWI assessment of a human gastric cancer xenograft**

Table 1 summarizes the ADC, D, f, and D* values of the tumors in the control and treatment groups, that were measured at baseline and at days 1, 3, 5 and 7. Figure 2 shows the mean percentage changes in the DWI parameters relative to baseline at each time point in each group. In the control group, all ADC values and IVIM parameters of the tumor remained relatively constant over the 7-d experiment. ADC increases in the treatment group (ΔADCtreatment, median, 30.10% ± 18.32%, 36.11% ± 21.82%, 45.22% ± 24.36%) were significantly higher compared with the control group (ΔADCcontrol, median, 4.98% ± 3.39%, 6.26% ± 3.08%, 9.24% ± 6.33%) at days 3, 5 and 7 (P = 0.008, P = 0.016, P = 0.008, respectively) (Figure 2A). Increases in D in the treatment group (ΔDtreatment, median 17.12% ± 8.20%, 24.16% ± 16.87%, 38.54% ± 19.36%) were higher than in the control group (ΔDcontrol, median -0.13% ± 4.23%, 5.89% ± 4.56%, 5.54% ± 4.44%) at days 1, 3, and 5 (P = 0.032, P = 0.008, P = 0.016, respectively) (Figure 2B). The relative changes in f were significantly lower in the treatment group than in the control group at days 1, 3, 5 and 7 follow-up (median, -34.13% ± 16.61% vs 1.68% ± 3.40%, P = 0.016; -50.64% ± 6.82% vs 3.01% ± 6.50%, P = 0.008; -49.93% ± 6.05% vs 0.97% ± 4.36%, P = 0.008, and -46.22% ± 7.75% vs 8.14% ± 6.75%, P = 0.008, respectively) (Figure 2C). D* in the treatment group decreased significantly compared with the control group at all time points (median, -32.10% ± 12.22% vs 1.85% ± 5.54%, P = 0.008; -44.14% ± 14.83% vs 2.29% ± 10.38%, P = 0.008; -59.06% ± 19.10% vs 3.86% ± 5.10%, P = 0.008, and -47.20% ± 20.48% vs 7.13% ± 9.88%, P = 0.016, respectively) (Figure 2D).

**Histopathological assessment of tumor response and its correlation with MR images**

HE, CD31 and TUNEL staining were performed to
Table 1  Summary of the apparent diffusion coefficient and intravoxel incoherent motion parameters at baseline (day 0) and on days 1, 3, 5, and 7 in each groups (n = 5 per group)

| ADC (10⁻³ mm²/s) | IVIM parameters | D* (mm²/s) |
|------------------|-----------------|------------|
|                  | D (10⁻³ mm²/s) | f (%)      |           |
| Control group    | Day 0           | 0.514 ± 0.050 | 0.480 ± 0.049 | 32.424 ± 6.647 | 0.112 ± 0.017 |
|                  | Day 1           | 0.520 ± 0.056 | 0.497 ± 0.052 | 33.010 ± 7.121 | 0.114 ± 0.016 |
|                  | Day 3           | 0.537 ± 0.029 | 0.506 ± 0.025 | 33.606 ± 8.113 | 0.115 ± 0.020 |
|                  | Day 5           | 0.545 ± 0.047 | 0.504 ± 0.021 | 32.602 ± 6.684 | 0.117 ± 0.018 |
|                  | Day 7           | 0.561 ± 0.053 | 0.524 ± 0.064 | 35.100 ± 7.588 | 0.120 ± 0.016 |
| 1-d treatment    | Day 0           | 0.555 ± 0.028 | 0.524 ± 0.028 | 34.076 ± 7.247 | 0.171 ± 0.049 |
| group            | Day 1           | 0.597 ± 0.064 | 0.612 ± 0.065 | 21.912 ± 5.032 | 0.115 ± 0.040 |
| 3-d treatment    | Day 0           | 0.528 ± 0.012 | 0.510 ± 0.019 | 37.066 ± 7.331 | 0.147 ± 0.025 |
| group            | Day 3           | 0.686 ± 0.107 | 0.636 ± 0.121 | 18.596 ± 5.766 | 0.083 ± 0.029 |
| 5-d treatment    | Day 0           | 0.594 ± 0.069 | 0.567 ± 0.065 | 34.664 ± 8.337 | 0.173 ± 0.068 |
| group            | Day 5           | 0.804 ± 0.136 | 0.777 ± 0.107 | 17.344 ± 4.352 | 0.070 ± 0.045 |
| 7-d treatment    | Day 0           | 0.560 ± 0.060 | 0.535 ± 0.081 | 37.598 ± 5.852 | 0.148 ± 0.082 |
| group            | Day 7           | 0.823 ± 0.221 | 0.710 ± 0.236 | 20.040 ± 3.042 | 0.065 ± 0.018 |

ADC: Apparent diffusion coefficient; IVIM: Intravoxel incoherent motion.

Figure 2  Comparison of the mean percentage changes from baseline in the intravoxel incoherent motion diffusion-weighted imaging derived values between the control (dark) and the 1-, 3-, 5- and 7-d treatment groups (grey). A: ADC value; B: D value; C: f value; D: D* value. Standard deviations are represented by vertical bars. Relative changes were determined by comparing the values at baseline and those in follow-up. *P < 0.05 vs control. n = 5 in each group. ADC: Apparent diffusion coefficient.
confirm the tissue and vessel changes in the tumor. Figure 3 shows the quantification of the NF, MVD, and cellular apoptosis in all animals of the control and the treatment groups \((n = 5\) per group). The MVD scores in 5-FU treatment tumors decreased significantly compared with the control group. The 5-FU treated tumors displayed a time-dependent increase in NF and cellular apoptosis compared to those in the control group, indicating an effective therapeutic response.

Table 2 summarizes the relationship among ADC, the IVIM parameters, MVD, cellular apoptosis and necrosis of tumors \((n = 25)\) determined by Spearman’s correlation coefficient analysis. ADC and D were positively correlated with NF \((r_s = 0.720, P < 0.001; r_s = 0.522, P = 0.007,\) respectively) (Figure 4A, B) and the cellular apoptosis of the tumor \((r_s = 0.626, P = 0.001; r_s = 0.542, P = 0.005,\) respectively) (Figure 4E, F). There is no significant correlation among ADC, D, and MVD. Perfusion-related parameters f and D* shows positive correlations with MVD \((r_s = 0.618, P = 0.001; r_s = 0.538, P = 0.006,\) respectively) (Figure 4C, D), and a negative correlation with the cellular apoptosis of the tumor \((r_s = -0.550, P = 0.004; r_s = -0.692, P < 0.001,\) respectively) (Figure 4G, H). There is no significant correlation between the perfusion parameters and NF. Figure 5 shows the calculated ADC, D, f, and D* maps and the correspondent histopathologic images from the control and 3 d treated mice.

**DISCUSSION**

The ADC obtained from conventional DWI has been widely accepted as a marker to monitor the therapeutic efficacy of chemotherapy, radiotherapy or combined therapy with target medicine\(^{[26,27]}\). In recent years, there has been a resurgent interest in IVIM studies, which allows to measure tissue diffusion and perfusion simultaneously. In this study, we performed IVIM-DWI using 12 \(b\)-values less than 800 \(s/mm^2\) to monitor the efficacy of chemotherapy in a mouse model of human gastric cancer. A histopathological analysis was carried out to evaluate the tissuecellularity and MVD properties of the tumor.

Our results demonstrated that conventional ADC significantly increased after 3-d of treatment and it showed a positive correlation with the 5-FU induced intratumoral necrosis and cellular apoptosis of the tumor. Papaevangelou et al\(^{[28]}\) found that ADC changes in the tumor were associated with the induction of a mixture of necrosis and apoptosis after irinotecan treatment. Therefore, ADC could be a reliable marker for detecting the necrotic and apoptotic cell death in gastric cancer patients during treatment. IVIM derived D values that showed a similar trend to ADC, were significantly increased as early as after one day treatment compared with the baseline values. Moreover, HE and TUNEL stain showed that D values were positively correlated with intratumoral necrosis and cellular apoptosis, indicating the possibility of a noninvasive evaluation of necrosis or apoptotic cell death.

Table 2 summarizes the relationship among ADC, the IVIM parameters, MVD, cellular apoptosis and necrosis of tumors \((n = 25)\) determined by Spearman’s correlation coefficient analysis. ADC and D were positively correlated with NF \((r_s = 0.720, P < 0.001; r_s = 0.522, P = 0.007,\) respectively) (Figure 4A, B) and the cellular apoptosis of the tumor \((r_s = 0.626, P = 0.001; r_s = 0.542, P = 0.005,\) respectively) (Figure 4E, F). There is no significant correlation among ADC, D, and MVD. Perfusion-related parameters f and D* shows positive correlations with MVD \((r_s = 0.618, P = 0.001; r_s = 0.538, P = 0.006,\) respectively) (Figure 4C, D), and a negative correlation with the cellular apoptosis of the tumor \((r_s = -0.550, P = 0.004; r_s = -0.692, P < 0.001,\) respectively) (Figure 4G, H). There is no significant correlation between the perfusion parameters and NF. Figure 5 shows the calculated ADC, D, f, and D* maps and the correspondent histopathologic images from the control and 3 d treated mice.

**DISCUSSION**

The ADC obtained from conventional DWI has been widely accepted as a marker to monitor the therapeutic efficacy of chemotherapy, radiotherapy or combined therapy with target medicine\(^{[26,27]}\). In recent years, there has been a resurgent interest in IVIM studies, which allows to measure tissue diffusion and perfusion simultaneously. In this study, we performed IVIM-DWI using 12 \(b\)-values less than 800 \(s/mm^2\) to monitor the efficacy of chemotherapy in a mouse model of human gastric cancer. A histopathological analysis was carried out to evaluate the tissue cellularity and MVD properties of the tumor.

Our results demonstrated that conventional ADC significantly increased after 3-d of treatment and it showed a positive correlation with the 5-FU induced intratumoral necrosis and cellular apoptosis of the tumor. Papaevangelou et al\(^{[28]}\) found that ADC changes in the tumor were associated with the induction of a mixture of necrosis and apoptosis after irinotecan treatment. Therefore, ADC could be a reliable marker for detecting the necrotic and apoptotic cell death in gastric cancer patients during treatment. IVIM derived D values that showed a similar trend to ADC, were significantly increased as early as after one day treatment compared with the baseline values. Moreover, HE and TUNEL stain showed that D values were positively correlated with intratumoral necrosis and cellular apoptosis, indicating the possibility of a noninvasive evaluation of necrosis or apoptotic cell death.

Table 2 summarizes the relationship among ADC, the IVIM parameters, MVD, cellular apoptosis and necrosis of tumors \((n = 25)\) determined by Spearman’s correlation coefficient analysis. ADC and D were positively correlated with NF \((r_s = 0.720, P < 0.001; r_s = 0.522, P = 0.007,\) respectively) (Figure 4A, B) and the cellular apoptosis of the tumor \((r_s = 0.626, P = 0.001; r_s = 0.542, P = 0.005,\) respectively) (Figure 4E, F). There is no significant correlation among ADC, D, and MVD. Perfusion-related parameters f and D* shows positive correlations with MVD \((r_s = 0.618, P = 0.001; r_s = 0.538, P = 0.006,\) respectively) (Figure 4C, D), and a negative correlation with the cellular apoptosis of the tumor \((r_s = -0.550, P = 0.004; r_s = -0.692, P < 0.001,\) respectively) (Figure 4G, H). There is no significant correlation between the perfusion parameters and NF. Figure 5 shows the calculated ADC, D, f, and D* maps and the correspondent histopathologic images from the control and 3 d treated mice.

**DISCUSSION**

The ADC obtained from conventional DWI has been widely accepted as a marker to monitor the therapeutic efficacy of chemotherapy, radiotherapy or combined therapy with target medicine\(^{[26,27]}\). In recent years, there has been a resurgent interest in IVIM studies, which allows to measure tissue diffusion and perfusion simultaneously. In this study, we performed IVIM-DWI using 12 \(b\)-values less than 800 \(s/mm^2\) to monitor the efficacy of chemotherapy in a mouse model of human gastric cancer. A histopathological analysis was carried out to evaluate the tissue cellularity and MVD properties of the tumor.

Our results demonstrated that conventional ADC significantly increased after 3-d of treatment and it showed a positive correlation with the 5-FU induced intratumoral necrosis and cellular apoptosis of the tumor. Papaevangelou et al\(^{[28]}\) found that ADC changes in the tumor were associated with the induction of a mixture of necrosis and apoptosis after irinotecan treatment. Therefore, ADC could be a reliable marker for detecting the necrotic and apoptotic cell death in gastric cancer patients during treatment. IVIM derived D values that showed a similar trend to ADC, were significantly increased as early as after one day treatment compared with the baseline values. Moreover, HE and TUNEL stain showed that D values were positively correlated with intratumoral necrosis and cellular apoptosis, indicating the possibility of a noninvasive evaluation of necrosis or apoptotic cell death.

Table 2 summarizes the relationship among ADC, the IVIM parameters, MVD, cellular apoptosis and necrosis of tumors \((n = 25)\) determined by Spearman’s correlation coefficient analysis. ADC and D were positively correlated with NF \((r_s = 0.720, P < 0.001; r_s = 0.522, P = 0.007,\) respectively) (Figure 4A, B) and the cellular apoptosis of the tumor \((r_s = 0.626, P = 0.001; r_s = 0.542, P = 0.005,\) respectively) (Figure 4E, F). There is no significant correlation among ADC, D, and MVD. Perfusion-related parameters f and D* shows positive correlations with MVD \((r_s = 0.618, P = 0.001; r_s = 0.538, P = 0.006,\) respectively) (Figure 4C, D), and a negative correlation with the cellular apoptosis of the tumor \((r_s = -0.550, P = 0.004; r_s = -0.692, P < 0.001,\) respectively) (Figure 4G, H). There is no significant correlation between the perfusion parameters and NF. Figure 5 shows the calculated ADC, D, f, and D* maps and the correspondent histopathologic images from the control and 3 d treated mice.
Table 2  Correlation between apparent diffusion coefficient and intravoxel incoherent motion parameters, microvessel density, cellular apoptosis and necrosis fraction of tumors ($n = 25$)

|                  | NF (%) |       |         |         |         |         |
|------------------|--------|-------|---------|---------|---------|---------|
|                  | $r_s$  | $P$ value | $r_s$  | $P$ value | $r_s$  | $P$ value |
| ADC ($\times 10^{-3} \text{ mm}^2/\text{s}$) | 0.720  | < 0.001 | -0.395  | 0.051 | 0.626  | 0.001 |
| IVIM parameters  |        |        |         |         |         |         |
| $D$ ($\times 10^{-3} \text{ mm}^2/\text{s}$) | 0.522  | 0.007 | -0.201  | 0.335 | 0.542  | 0.005 |
| $f$ (%)          | -0.347 | 0.089 | 0.618   | 0.001 | -0.550 | 0.004 |
| $D^*$ ($\times \text{ mm}^2/\text{s}$)       | -0.378 | 0.062 | 0.538   | 0.006 | -0.692 | < 0.001 |

$P < 0.05$ is considered to be statistically significant. ADC: Apparent diffusion coefficient; IVIM: Intravoxel incoherent motion; MVD: Microvessel density; NF: Necrosis fraction.
and represents the true molecular diffusion, would eventually translate into a reliable marker to evaluate the tumor therapy response.

The $f$ and $D*$ significantly decreased during the early phase of chemotherapy. In addition, the $f$ and $D*$ were well correlated with the decrease in MVD revealed by the endothelial cell marker CD31 staining, which indicated that $f$ and $D*$ have the potential to assess tumor angiogenesis activity noninvasively. There are experimental and clinical dates in body tissues with IVIM-DWI which support the claim that the signal attenuation is related to microcirculation in tissue when $b$-values less than 100 s/mm$^2$ were applied. Wang et al.[30] found an increase in the tumor blood flow induced by IV hydralazine injection was accompanied by an increase in the IVIM-derived $D$ in a mammary adenocarcinoma rat model. In a human brain study, $f$ and $D^*$ were correlated separately with the relative blood volume and blood flow derived from dynamic susceptibility contrast enhancement imaging[31]. Joo et al.[19] reported that IVIM-DWI has the potential to evaluate the early therapeutic effect induced by a vascular disrupting agent named CKD-516 in rabbit VX2 liver tumors. In addition, $f$ and $D^*$ also showed a weak negative correlation with the cellular apoptosis of the tumor, indicating that the decreased cellularity also contributed to the changes in $f$ and $D^*$. This may reconfirm the finding that tissue water diffusion also contributes to the observed signal attenuation at low $b$-values. After effective chemotherapy, extracellular spaces would expand, resulting in less restriction of migration of water molecules and weakening the process of pseudo-diffusion. This would then yield a higher $D$ value and lower $f$ and $D^*$ than those obtained pre-treatment. Our results and the conclusions from previous studies[13,32] indicated the usefulness of IVIM-DWI for depicting the therapeutic efficiency in gastric cancer before changes in tumor size are evident.

The option of a bi-exponential model for extracting molecular diffusion and microcirculation perfusion information from DWI remains controversial. A previous IVIM study with the $b$-values up to 1500 s/mm$^2$ found that $f$ increased after treatment, which contradicts our finding[21]. Pang et al.[23] found that $f$ obtained from $b$-values below 750 s/mm$^2$ is more in keeping with the increased perfusion in prostate cancer tissue, while $f$ decrease or became indistinguishable from the normal level of prostate tissue when high $b$-values employed. Both tissue microcirculation and water diffusion in the tissue contributed to signal attenuation at a low $b$-value; hence, departure of molecular diffusion at very high $b$-values may influence the perfusion-related parameters[33,34]. Moreover, the IVIM method suffers significantly from the variations in the signal-to-noise ratio and is prone to generate measurement errors when $b$-values are lower than 100 s/mm$^2$[13]. To date, no consensus has been reached on the magnitude and number of $b$-values that ought to be applied in preclinical and clinical studies. Therefore, more studies are required to optimize the process of image collection and image post-processing for deriving sufficiently accurate parameters based on the original IVIM model.

There are limitations to this study. First, the observation endpoint in this study is too short. Secondly, because of the small sample sizes, serial relative changes in ADC and the IVIM parameters of the tumor were not evaluated in the treatment groups. Therefore, we need further studies with larger sample size and long-term observations to clarify the limitation of this study.

In conclusion, IVIM-DWI raises the possibility of an effective, multi-parametric ($D$, $f$, $D^*$) imaging method without requirement of gadolinium enhancement. The IVIM method could potentially be used to assess tissue diffusivity changes in addition to evaluate the microcirculatory perfusion of gastric cancer in response...
to chemotherapy.

ACKNOWLEDGMENTS
The authors thank Mr. Kim Don Geun GE Healthcare for magnetic resonance imaging technical support and Pro of Moon Jai Dong Chonnam National University Medical School for advice on statistic analysis.

COMMENTS

Background
Chemotherapy is a standard treatment for advanced gastric cancer. Imaging modalities that help to identify early and reliable surrogate markers for the evaluation of chemotherapy response are important in patients with gastric cancer. Intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI), which allows acquisition of quantitative parameters that reflect tissue diffusivity and tissue microvascular perfusion, maybe a useful tool that can monitor the early chemotherapy response in terms of gastric cancer tissue diffusion and microvascular perfusion.

Research frontiers
IVIM-DWI has been used to monitor the treatment responses to radiofrequency ablation or a vascular disrupting agent of CKD-516 in rabbit model with VX2 liver tumors, and the response of human locoregionally advanced nasopharyngeal carcinoma to neoadjuvant chemotherapy. DWI is increasingly being applied in the human body, but few studies focused on the gastric lesions due to the limitation of the modality.

Innovations and breakthroughs
In this study, IVIM-DWI with 12 b-values less than 800 s/mm² was performed to avoid the potential impact of higher b-values on the accuracy of the IVIM-derived parameters.

Applications
IVIM-DWI raises the possibility of an effective, multi-parametric (D, f, D*) imaging method that does not require gadolinium enhancement. The IVIM method could potentially be used to assess tissue diffusivity changes in addition to measuring the microcirculatory perfusion of gastric cancer in response to
Terminology

DWI is capable of providing a parameter of apparent diffusion coefficient (ADC). The measured ADC, which represents tissue diffusivity, has become a favorite choice in oncologic studies. IVIM-DWI allows acquisition of multi-quantitative parameters that reflect tissue diffusivity and microcirculation perfusion.

REFERENCES

1. Carcas L.P. Gastric cancer review. J Carcinog 2014; 13: 14 [PMID: 25589897 DOI: 10.4103/1477-3163.146506]
2. Spampatti S, Rausei S, Galli F, Ruspi L, Peverelli C, Frattini F, Rovera F, Boni L, Dionigi G. Neoadjuvant chemotherapy for locally advanced gastric cancer: the surgeon’s role. Trans Gastrointest Cancer Oncol 2015; 4: 141-147 [DOI: 10.3978/j.issn.2224-4778.2014.12.02]
3. Dikgila A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016; 22: 2403-2414 [PMID: 26937129 DOI: 10.3748/wjg.v22.i8.2403]
4. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver 2013; 7: 385-393 [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385]
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oostrom AT, Christian MC, Gomez RG, Sargent DJ, Whittaker N. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216 [PMID: 10655437 DOI: 10.1093/jnci/92.3.205]
6. Sadeghi-Naini A, Falou O, Hudson JM, Bacon J, Burns PN, Yaffe MJ, Stanisz GJ, Kolios MC, Czarnota GJ. Imaging innovations for cancer therapy response monitoring. Imaging Med 2012; 4: 311-327 [DOI: 10.2217/imr.12.23]
7. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebski BS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, Chenevert TL. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003; 2: 581-587 [PMID: 12813138]
8. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010; 49: 354-360 [PMID: 20397769 DOI: 10.3109/02841861003618184]
9. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900 [PMID: 18710982 DOI: 10.1148/radiol.2483071407]
10. Siegel MJ, Jokert CE, Rajderkar D, Hildebolt CF, Goyal S, Dedhasti F, Wagner Johnston N, Siegel BA. Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. NMR Biomed 2014; 27: 681-691 [PMID: 24700565 DOI: 10.1002/nbm.3105]
11. Wu X, Kelloggumpu-Lehtinen PL, Pertovaara H, Kirkola P, Soimakallio S, Eskola H, Dastidar P. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma—a pilot study: comparison with 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography. NMR Biomed 2011; 24: 1181-1190 [PMID: 21387451 DOI: 10.1002/nbm.1689]
12. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401-407 [PMID: 3763909 DOI: 10.1148/radiology.161.2.3763909]
13. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011; 196: 1351-1361 [PMID: 21606299 DOI: 10.224/AJR.10.58515]
14. Kang KM, Lee JM, Yoon JH, Kieffer B, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for characterization of focal pancreatic lesions. Radiology 2014; 270: 444-453 [PMID: 24126370 DOI: 10.1148/radiol.13122712]
15. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505 [PMID: 3393671 DOI: 10.1148/radiology.168.2.3393671]
16. Koh DM, Scurr E, Collins DJ, Pirgon A, Kanber B, Karanja N, Brown G, Leach MO, Husband JE. Coloroetal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. Eur Radiol 2006; 16: 1898-1905 [PMID: 16691378 DOI: 10.1007/s00330-006-0201-x]
17. Eisenberger U, Thoeny HC, Binser T, Gugger M, Frey FJ, Boesch C, Vermathen P. Evaluation of renal allograft function early after transplantation with diffusion-weighted MR imaging. Eur Radiol 2010; 20: 1374-1383 [PMID: 20013274 DOI: 10.1007/s00330-009-1679-9]
18. Guo Z, Zhang Q, Li X, Jing Z. Intravoxel Incoherent Motion Diffusion Weighted MR Imaging for Monitoring the Instantly Therapeutic Efficacy of Radiofrequency Ablation in Rabbit VX2 Tumors without Evident Links between Conventional Perfusion Weighted Images. PLoS One 2015; 10: e0127964 [PMID: 26020785 DOI: 10.1371/journal.pone.0127964]
19. Joo JI, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disappearing agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014; 272: 417-426 [PMID: 24697148 DOI: 10.1148/radiol.14132429]
20. Xiao Y, Pan J, Chen Y, Chen Y, He Z, Zheng X. Intravoxel Incoherent Motion-Magnetic Resonance Imaging as an Early Predictor of Treatment Response to Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. Medicine (Baltimore) 2015; 94: e973 [PMID: 26091468 DOI: 10.1097/MD.0000000000000973]
21. Cheng J, Zhang C, Wang H, Wu W, Pan F, Hong N, Wang Y. Evaluation of chemotherapy response of gastric cancer in a mouse model using intravoxel incoherent diffusion-weighted MRI correlated with histopathological characteristics. ECR 2015; C-0536 [DOI: 10.1594/ecr2015/C-0536]
22. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7: 3670-3684 [PMID: 19074844 DOI: 10.1158/1535-7163.MCT-08-0715]
23. Pang Y, Turkbey B, Bernardo M, Knuecker J, Kadoury S, Merino MJ, Wood BJ, Pinto PA, Choyke PL. Intravoxel incoherent motion diffusion-MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med 2013; 69: 553-562 [PMID: 22488794 DOI: 10.1002/mrm.24277]
24. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8 [PMID: 1705159 DOI: 10.1056/NEJM199103303241201]
25. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed. Boston: Houghton Mifflin, 2003: 89-90
26. Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuramati M, Watanabe M, Hayakawa K. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent
diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. *J Comput Assist Tomogr* 2005; 29: 644-649 [PMID: 16163035 DOI: 10.1097/01.rct.0000171913.74086.1b]

27 **Langer DL**, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. *J Magn Reson Imaging* 2009; 30: 327-334 [PMID: 19629981 DOI: 10.1002/jmri.21824]

28 **Papaevangelou E**, Almeida GS, Jamin Y, Robinson SP, deSouza NM. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. *Br J Cancer* 2015; 112: 1471-1479 [PMID: 25880014 DOI: 10.1038/bjc.2015.134]

29 **Wang YC**, Hu DY, Hu XM, Shen YQ, Meng XY, Tang H, Li Z. Assessing the Early Response of Advanced Cervical Cancer to Neoadjuvant Chemotherapy Using Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging: A Pilot Study. *Chin Med J (Engl)* 2016; 129: 665-671 [PMID: 26960369 DOI: 10.4103/0366-6999.177995]

30 **Wang Z**, Su MY, Najafi A, Nalcioglu O. Effect of vasodilator hydralazine on tumor microvascular random flow and blood volume as measured by intravoxel incoherent motion (IVIM) weighted MRI in conjunction with Gd-DTPA-Albumin enhanced MRI. *Magn Reson Imaging* 2001; 19: 1063-1072 [PMID: 11711230 DOI: 10.1016/S0730-725X(01)00431-3]

31 **Wirestam R**, Borg M, Brockstedt S, Lindgren A, Holtás S, Ståhlberg F. Perfusion-related parameters in intravoxel incoherent motion MR imaging compared with CBV and CBF measured by dynamic susceptibility-contrast MR technique. *Acta Radiol* 2001; 42: 123-128 [PMID: 11281143 DOI: 10.1080/028418501127346459]

32 **Shinmoto H**, Tamura C, Soga S, Shiomi E, Yoshihara N, Kaji T, Mulkern RV. An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer. *AJR Am J Roentgenol* 2012; 199: W496-W500 [PMID: 22997399 DOI: 10.2214/AJR.11.8347]

33 **Jensen JH**, Helpenn JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. *NMR Biomed* 2010; 23: 698-710 [PMID: 20632416 DOI: 10.1002/nbm.1518]

34 **Shinmoto H**, Oshio K, Tanimoto A, Higuchi N, Okuda S, Kuriyabashi S, Mulkern RV. Biexponential apparent diffusion coefficients in prostate cancer. *Magn Reson Imaging* 2009; 27: 355-359 [PMID: 18768281 DOI: 10.1016/j.mri.2008.07.008]

**P- Reviewer:** Goetze TO, Martin-Villa JM, Zhang J  **S- Editor:** Ma YJ  **L- Editor:** A  **E- Editor:** Zhang DN
